Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Cardiff Oncology Inc. is managing a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 4 pending office actions. These actions are distributed among 4 distinct examiners, which means that each examiner is currently reviewing a single case. The prosecution activity is also spread across 4 distinct art units, indicating a high level of technical or procedural variety within the company's active filings.
BRAUN, MADELINE E is the busiest examiner for the portfolio, with 1 pending office action. Given that there are 4 distinct examiners for the 4 pending actions, the workload is evenly distributed across the individuals involved. The fact that there are 4 distinct art units for 4 pending actions is significant: every active case is being reviewed in a different specialized division of the patent office. For a practitioner, this requires managing four different examiner relationships and navigating the specific guidelines of four separate art units simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.6% | +24.8% |
| MCKOY, QUINCY ANDRE | 1 | 69.2% | +39.4% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 48.6% | +79.2% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710027 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | BRAUN, MADELINE E | — |
| 18554158 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | MCKOY, QUINCY ANDRE | — |
| 17433440 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | MOU, LIYUAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923803 | METHODS OF MONITORING KRAS MUTATIONS | JOHNSON, CHRISTOPHER LINDSAY | 13d |
| 18710027 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | BRAUN, MADELINE E | — |
| 18554158 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | MCKOY, QUINCY ANDRE | — |
| 17433440 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1626 | 1 |
| 1691 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710027 | CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS | BRAUN, MADELINE E | 1624 | §103§112 | Non-Final OA | — | Pending | May 14, 2024 |
| 18554158 | CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS | MCKOY, QUINCY ANDRE | 1626 | §103§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 17923803 | METHODS OF MONITORING KRAS MUTATIONS | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §112 | Non-Final OA | 13d | Pending | Apr 28, 2023 |
| 17433440 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | MOU, LIYUAN | 1628 | §103§112 | Final Rejection | — | Pending | Aug 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCardiff Oncology Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.
Madeline E Braun has the most, with 1 of Cardiff Oncology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.